Abstract
Mr. Michael W. Bonney, B.A., Partner at Third Rock Ventures, LLC and former CEO of Cubist Pharmaceuticals Inc., discusses his personal experience with using comparative effectiveness research in decision making while presiding over Cubist. He also considers how the introduction of the Affordable Care Act and increasing interest in the budget impact of the pricing of recent pharmaceuticals are changing health care decision making and impacting manufacturer decision making.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Patient Protection and Affordable Care Act (2010) HR 3590. 111th Congress, vol 2. USA
Institute for Clinical and Economic Review (ICER) (2015) PCSK9 inhibitor therapies for high cholesterol: effectiveness, value, and value-based price benchmarks
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2017 Springer Nature Singapore Pte Ltd.
About this chapter
Cite this chapter
Bonney, M.W., Birnbaum, H.G. (2017). Perspectives on the Use of Comparative Effectiveness Research by Life Sciences Executives: An Interview with Mike Bonney. In: Birnbaum, H., Greenberg, P. (eds) Decision Making in a World of Comparative Effectiveness Research. Adis, Singapore. https://doi.org/10.1007/978-981-10-3262-2_3
Download citation
DOI: https://doi.org/10.1007/978-981-10-3262-2_3
Published:
Publisher Name: Adis, Singapore
Print ISBN: 978-981-10-3261-5
Online ISBN: 978-981-10-3262-2
eBook Packages: MedicineMedicine (R0)